Anthrax
Drug research and approvals for anthrax: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 3 studies of anthrax are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 5 approved and 4 open orphan designations naming it.
- Recruiting worldwide: 3
- Trials authorized in Canada: 0
- FDA orphan approvals: 5
- EU medicines: 0
Recruiting now
Newest start dates first, of 3 recruiting on ClinicalTrials.gov ↗- Combined Gastrointestinal Decontamination in Acute Severe PoisoningNCT07201311 · Phase 2 · Assistance Publique - Hôpitaux de Paris · starts Jun 24, 2026
- Cigarette Filter StudyNCT07348679 · Not applicable · Rutgers, The State University of New Jersey · starts Apr 27, 2026
- Activated CHARcoal in Poisoned Patient - Pilot TrialNCT05471479 · Phase 4 · Laval University · starts Jul 16, 2025
Drug pipeline
4 approved, 3 in phase 2, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Obiltoxaximab, Doxycycline anhydrous, Raxibacumab, Bacillus anthracis protective antigen, adsorbed
- Ciprofloxacin
- Phase 2 Bacterial DNA gyrase inhibitor
- Aluminum hydroxide
- Phase 2 Antacid
- Anthrax vaccine absorbed
- Phase 2 Biological vaccine - induces immune response
- MDX-1303
- Phase 1 Protective antigen inhibitor
- Human immunoglobulin g
- Phase 1 Replacement therapy, immunomodulatory effects
- AVP-21D9
- Phase 1 Protective antigen inhibitor
How its trials ended
52 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 12 whose ending is known, 58% met their primary endpoint, 8% missed it and 33% stopped early.
- Completed, result not reported3465%
- Met its primary endpoint713%
- Ongoing612%
- Stopped: sponsor or business decision24%
- Stopped: other or unclear24%
- Missed its primary endpoint12%
FDA orphan designations
Approved first, then open designations, newest first| Jul 20, 2023 | CyfendusPost-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age… | Emergent Product Development Gaithersburg, Inc. | Approved |
| Mar 18, 2016 | AnthimTreatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial… | Elusys Therapeutics, Inc. | Approved |
| Nov 23, 2015 | BioThraxFor post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction… | Emergent BioDefense Operations Lansing LLC | Approved |
| Mar 24, 2015 | Anthrax immune globulin (human)Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs | Cangene Corp. - Emergent Biosolutions | Approved |
| Dec 14, 2012 | ABthraxTMTreatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, | Human Genome Sciences, Inc. | Approved |
| Apr 26, 2026 | Omadacycline p-toluenesulfonatePost-exposure prophylaxis (PEP) of anthrax infection | Paratek Pharmaceuticals, Inc. | Designated |
| Apr 26, 2026 | Omadacycline p-toluenesulfonateTreatment of anthrax | Paratek Pharmaceuticals, Inc. | Designated |
| Jun 21, 2018 | L-alanoyl-D-glutamate endopeptidase from Bacillus-infected…Treatment of inhalational anthrax | iNtRON Biotechnology, Inc. | Designated |
| Feb 28, 2007 | CethromycinProphylactic treatment of patients exposed to inhalation anthrax. | Advanced LIfe Sciences, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA